While the mechanisms of EZH2 and PRC2 dysregulation in leukemia development and progression are progressively better understood, it is important to view aberrations in the bigger picture of a heterogeneous molecular background with multiple genetic lesions contributing to pathogenesis in the majority of myeloid malignancies. This evidence concerns the gene EZH2 and leukemia.